Lung Cancer News and Research

Latest Lung Cancer News and Research

ArQule reports net loss of $1,466,000 for first quarter 2011

ArQule, Inc. today announced its financial results for the first quarter of 2011.

5 May 2011

ZIOPHARM reports net loss of $39.0 million for first quarter 2011

ZIOPHARM Oncology, Inc, an oncology small molecule and synthetic biology drug development company, today reported its financial results for the three months ended March 31, 2011, and provided an update on the Company's activities in the first quarter.

5 May 2011

ChipDX identifies gene expression signature in early-stage breast tumors

ChipDX LLC, a New York-based molecular diagnostics and personalized medicine research company, has discovered a gene expression signature present in the cells of early-stage breast tumors that indicates the chance of the tumor recurring within 10 years.

4 May 2011

New nano-vault delivery system can fight cancer

UCLA scientists have discovered a way to wake up the immune system to fight cancer by delivering an immune system-stimulating protein in a nanoscale container called a vault directly into lung cancer tumors, harnessing the body's natural defenses to fight disease growth.

4 May 2011

Study shows how secondhand smoke may increase vulnerability to nicotine addiction

Exposure to secondhand smoke, such as a person can get by riding in an enclosed car while someone else smokes, has a direct, measurable impact on the brain-and the effect is similar to what happens in the brain of the person doing the smoking.

3 May 2011

Temsirolimus with chemotherapy may serve as promising therapy for mesothelioma

A drug commonly used to treat kidney cancer may increase the effectiveness of chemotherapy for mesothelioma, according to a study published in the May issue of the Journal of Thoracic Oncology.

2 May 2011

Bristol-Myers Squibb first quarter net sales increase 5% to $3.3 billion

Bristol-Myers Squibb Company today announced first quarter results that included strong sales and earnings growth, and several key R&D milestones—most notably U.S. regulatory approval for YERVOY. The company also confirmed guidance for the year.

30 Apr 2011

Oncothyreon prices underwritten public offering of common stock

Oncothyreon Inc. today announced that it has priced an underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $4.00 per share for gross proceeds of $40.0 million. The net proceeds from the sale of the shares, after deducting the underwriters' discounts and other estimated offering expenses payable by Oncothyreon, will be approximately $37.4 million.

29 Apr 2011

Biodesix announces patient enrollment for VeriStrat CASTLE study in lung cancer

Biodesix announces the enrollment of initial subjects into CASTLE, the inaugural study of the Addario Lung Cancer Medical Institute.

29 Apr 2011

MorphoSys reaches second clinical milestone with OncoMed Pharmaceuticals

MorphoSys AG announced today that it has received a milestone payment from OncoMed Pharmaceuticals in connection with the FDA acceptance of an IND for a HuCAL-derived, fully human antibody. The antibody OMP-18R5, which targets the Wnt signaling pathway, will be evaluated in a Phase 1 trial in the US in patients with advanced solid tumors.

29 Apr 2011

Drug subsidy issues out of PBS’ hands - almost

According to Health Minister Nicola Roxon, expensive drugs have never been automatically listed for subsidy and they can't be now when the government controlling expenses. She added that federal Labor has to balance competing priorities in health and every other department.

29 Apr 2011

New PET imaging clinical trial to improve early esophageal, lung cancer detection

Can a simple imaging test help predict the success of cancer treatment, even before the treatment is complete? To begin to answer this question, a new National Cancer Institute-funded clinical trial is using a novel PET imaging technique that could improve the early detection of tumor growth during treatment for esophageal and lung cancer.

29 Apr 2011

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Celgene Corporation: “The results for the quarter were outstanding and they reflect the ongoing momentum that Celgene is creating as we leverage our business model and position our Company for long-term success”.

28 Apr 2011

AVEO reports total revenue of $133.6 million for first quarter 2011

AVEO Pharmaceuticals, Inc. today reviewed key first quarter accomplishments and reported consolidated financial results for the first quarter of 2011.

28 Apr 2011

ASTRO develops new thoracic radiotherapy guideline

The American Society for Radiation Oncology has developed a guideline for the use of external beam radiation therapy, endobronchial brachytherapy and concurrent chemotherapy to palliate thoracic symptoms caused by advanced lung cancer. The guideline will be published in Practical Radiation Oncology, an official journal of ASTRO.

28 Apr 2011

Deep Breeze launches telehealth Breeze@home system for COPD patients

Deep Breeze Ltd, the leader in Vibration Response Imaging technology, today announced that it is introducing its telehealth Breeze@homeT system, the first in-home quantitative approach to COPD lung monitoring.

28 Apr 2011

Low-cost colorimetric sensing array identifies bacterial infections

Bacterial infections really stink. And that could be the key to a fast diagnosis.

28 Apr 2011

Riverain Medical's bone suppression technology effective for lung nodule detection

Riverain Medical, an industry leader and innovator in computer-aided detection and advanced visualization technologies, today announced the publication of a peer-reviewed observer study in the May 2011 issue of the American Journal of Roentgenology.

27 Apr 2011

CESAR, Saladax begin patient enrollment in paclitaxel CEPAC-TDM trial for NSCLC

In collaboration with Saladax Biomedical, Inc., the Central European Society for Anticancer Drug Research announced today that enrollment has begun in the CEPAC-TDM trial of paclitaxel therapeutic drug management with subsequent pharmacokinetic-guided dose adjustment in patients being treated for advanced non-small cell lung cancer.

27 Apr 2011

Heparan sulfate may have a key role in tumor-spurred lymphatic vessel growth

Cancer has a mighty big bag of tricks that it uses to evade the body's natural defense mechanisms and proliferate. Among those tricks is one that allows tumor cells to turn the intricate and extensive system of lymphatic vessels into something of a highway to metastasis. Yet research unveiled this week may aid in the development of therapeutics that will put the brakes on such cancer spread, and the researchers who completed the study say the findings may extend to other lymphatic disorders.

27 Apr 2011